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Abstract
Monitoring, evaluation, and surveillance measure how
well public health programs operate over time and
achieve their goals. As countries approach malaria
elimination, these activities will need to shift from
measuring reductions in morbidity and mortality, to
detecting infections (with or without symptoms) and
measuring transmission. Thus, the monitoring and eval-
uation and surveillance research and development
agenda needs to develop the tools and strategies that
will replace passive surveillance of morbidity with active
and prompt detection of infection, including confirmation
of interruption of transmission by detecting present and
past infections, particularly in mobile populations. The
capacity to assess trends and respond without delay will
need to be developed, so that surveillance itself becomes
an intervention. Research is also needed to develop
sensitive field tests that can detect low levels of
parasitaemia, together with strategies for their implemen-
tation. Other areas to explore include the rigorous
evaluation of the utility of more detailed maps of disease
and infection incidence and prevalence, the development
of new maps to inform programmatic responses and the
use of surveillance technologies based on cell phone or
real-time internet Web-based reporting. Because any new
strategies for monitoring and evaluation and surveillance
for eradication have major implications for program
implementation, research is also needed to test systems
of delivery for acceptability, feasibility, efficiency, cost-
effectiveness, and community engagement. Finally, there
is a clear need to systematically review the information
from past elimination efforts for malaria and other
infectious diseases.
Introduction
Monitoring (the systematic tracking of program actions over
time) and evaluation (the examination of progress and its
determinants) activities measure how well public health programs
operate over time and whether they are achieving their program
milestones (markers of progress within and transition between
phases) and ultimate goals. In the context of malaria program
scale-up, monitoring and evaluation focuses on the evaluation of
burden reduction, specifically morbidity and mortality [1].
However, as programs successfully reduce transmission to near-
elimination levels, the measurement of malaria-associated mor-
bidity and mortality burden becomes increasingly difficult and
insensitive, particularly since a substantial proportion of infections
will be asymptomatic in countries that experienced high infection
rates in the recent past. Thus, burden measures that only detect
clinical illness will not provide good estimates of ongoing
transmission as countries approach elimination, and malaria
program monitoring and evaluation and surveillance methods
will need to focus on detecting infections (with or without
symptoms) and measuring transmission dynamics as the primary
indicators of interest.
The malERA Consultative Group on Monitoring, Evaluation,
and Surveillance focused on defining the monitoring and
evaluation and surveillance research and development needs as
malaria elimination efforts unfold over the next 5–20 years.
Information gaps and research needs were identified by the group
by considering several broad thematic areas: lessons learned from
countries that have recently achieved malaria elimination [2] or
elimination of other diseases; the required evolution of the malaria
monitoring and evaluation framework and indicators; surveillance
as an intervention to reduce transmission; measurement of
transmission interruption and maintenance of zero transmission;
the tools (currently available and in the pipeline) needed, including
diagnostics (screening, confirmation, and transmission measure-
ment), mapping, and communication; and implementation issues.
Information and research needs that were identified include:
systematic reviews of existing information and experience, and
assembly of that work into guidance; protocol or standards
development for conduct of certain activities; and research and
development activities to produce new information where
guidance or experience does not exist, and new tools where these
will enhance capabilities.
The World Health Organization (WHO) and the Roll Back
Malaria (RBM) Global Malaria Action Plan (GMAP) characterize
different ‘‘phases’’ of malaria control as programs progressively
reduce transmission, though it is understood that these phases are
part of a continuum rather than abrupt shifts [3,4]. At high levels
of transmission, initial efforts are focused on scaling up for impact
(SUFI). Sustained control efforts subsequently lead to further
transmission reduction. As very low levels of transmission are
reached, programs move from a focus on control to a focus on pre-
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tion. Where appropriate, we shall indicate where proposed
research and development activities would fit into this malaria
elimination framework.
Lessons Learned from Other Diseases or Current
Malaria Elimination Programs
Several diseases other than malaria have been proposed for
eradication or elimination. General lessons learned from these
other disease elimination efforts have been summarized and
underscore the critical role that monitoring and evaluation and
surveillance play in these efforts [5–9]. The essential role of
monitoring and evaluation and surveillance in informing elimina-
tion program efforts is particularly clear in past smallpox efforts
and ongoing polio activities. Many countries have either
eliminated or are in the process of pursuing malaria elimination.
There is, therefore, a clear need to systematically review and
summarize the monitoring and evaluation and surveillance lessons
learned from both successful and unsuccessful disease elimination
programs. In the context of malaria elimination, efforts are
underway to summarize and disseminate recently accrued
experience [2,10]. This review work should be done even before
the elimination phase.
General needs for monitoring and evaluation and surveillance
that have already emerged from experience with elimination
efforts for malaria and for other diseases include the need for:
improved management of systems; improved identification of
infected individuals; enhanced methods for engaging and
developing community support; improved information sharing
for advocacy (at the community level and involving high level
leaders); and improved ways of conducting surveillance activities in
the private sector. Past experience also indicates that current and
future tools and strategies for monitoring and evaluation and
surveillance will need to be tailored to the individual epidemio-
logical, entomological, and socio-cultural situation.
Monitoring and Evaluation Framework and
Indicators
The current Monitoring and Evaluation Framework for malaria
comprises a series of activities, namely, Assessments and Planning,
Inputs, Processes, Outputs, Outcomes (intermediate effects), and
Impact (long-term effects; Figure 1A) [1]. Each part of this schema
can be monitored with a specific set of indicators that tracks
progress in program implementation. Historically, the malaria
community has focused on illness and mortality reduction as
indicators of impact, but will these and the other current indicators
shown in Figure 1A serve us well for elimination efforts?
There is general consensus that these coverage indicators will
continue to be useful because high intervention coverage will need
to be maintained en route to elimination, especially in Africa
where transmission is intense. However, as elimination is
approached, other indicators will need to be adapted and new
ones will need to be introduced. For example, indicators that track
the proportion of cases with parasitological confirmation or that
focus on coverage of individuals in specific geographic areas where
foci of transmission are located will be needed. Similarly, if
transmission blocking vaccines are deployed, coverage with the
vaccine will need to be tracked. The utility of indicators and
databases for parasite strain information that could differentiate
indigenous from imported cases may need to be evaluated. In
addition, methods and indicators for tracking population move-
ments within and between countries and quantifying their
contribution to the risk of malaria transmission may be useful.
Furthermore, greatly reduced malaria morbidity and mortality
levels (achieved through intervention scale-up and sustained
control) will need to be monitored, although ultimately, as
elimination approaches, the measure of impact will need to be
infection and transmission (sometimes from introduced cases), and
programs will need to include active case detection and case-based
investigation and response within a revised Monitoring and
Evaluation Framework (Figure 1B) (also see [11,12]).
Surveillance as an Intervention
As noted in the Introduction, monitoring and evaluation are
critically required for measurement of malaria control program
success. Over time, the term ‘‘surveillance’’ has become somewhat
synonymous to some with monitoring and evaluation, but the
WHO Global Malaria Eradication Program (GMEP), which
lasted from 1955 to 1969, defined surveillance quite specifically as
an integral action or intervention within that eradication program
(Box 1) [13].
Malaria programs contemplating an elimination strategy must
be prepared to change their strategies of monitoring and
evaluation and surveillance as transmission is reduced [14,15].
Thus, many countries begin scale-up of malaria control interven-
tions with relatively high levels of malaria transmission and
develop monitoring and evaluation programs that rely on the
collection of routine information (often from health facilities and
health management information systems) and on periodic
population-based surveys. Together, these approaches collect
information on intervention coverage and use as well as changes
in malaria burden, but, as transmission intensity drops to near
elimination levels, surveillance as defined by GMEP needs to
increase (Table 1).
In the context of malaria elimination programs, the goal is to
achieve complete reporting of each case of infection to health
authorities, regardless of whether symptoms of fever or illness are
present. Critically, malaria control programs usually identify
individuals with fever/symptoms and laboratory-confirmed ma-
laria parasite infection as ‘‘malaria cases,’’ but do not systemat-
ically assess the extent of asymptomatic malaria infection. As
transmission decreases and individuals have less exposure to
malaria, they lose acquired immunity and a higher proportion of
Summary Points
N As countries approach malaria elimination, monitoring,
evaluation, and surveillance activities will need to shift
from measuring morbidity and mortality to detecting
infections and measuring transmission
N Diagnostic tools (in particular, practical, field-ready tools
for the detection of asymptomatic infection and DNA-
based and serological biomarkers for malaria infection
and transmission), and methods for tracking population
movements will need to be developed and improved
N Development and use of better malaria distribution
maps to guide elimination efforts requires more research
N Research is needed to assess and compare the
performance of malaria transmission metrics at near
zero transmission; new metrics will need to be devel-
oped for use in this setting
N Research should also be undertaken to test and improve
the feasibility, efficiency, and cost-effectiveness of new
information systems
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rapid transition from high exposure to low exposure, the
proportion of persons with enough acquired immunity to harbour
asymptomatic infections may remain substantial [16]. For
example, in a low transmission setting in the western Pacific,
.80% of infections identified in a recent cross-sectional
population-based survey were afebrile [17]. Because asymptomatic
infections are a reservoir of transmission to others, it is critical to
seek all infections rather than just symptomatic cases as a method
to reduce transmission.
For surveillance, standardized definitions for case/infection
reporting are needed, along with a strong mandate for notification
to health authorities of all malaria cases/infections in both public
and private settings [18]. An important area for further research,
therefore, is to investigate how tools such as legal requirements,
financial inducements, and other novel approaches can be used to
improve the coordination of detection and reporting of infections
from the private sector to public health authorities. Importantly,
all malaria cases/infections must be epidemiologically investigated,
and linked to geographic and laboratory data (species and
genotyping) so that the source and potential spread of infection
can be quickly addressed.
Furthermore, reporting systems must be able to analyze
reported data rapidly to assess trends over time and place,
particularly as transmission drops and cases of infection become
increasingly focal in distribution [19]. Although some control
programs in endemic areas have malaria early warning systems,
these systems need better performance characteristics (for
example, better linkages with local information systems) before
they can be truly useful in malaria elimination.
Figure 1. (A) Malaria monitoring and evaluation framework and illustrative data types. Source: adapted from [3]. (B) Evolving malaria monitoring and
evaluation framework with emphasis on transmission. Image credit: Fusio ´n Creativa.
doi:10.1371/journal.pmed.1000400.g001
Box 1. Definitions of Surveillance
Per conventional use: Surveillance is the ongoing,
systematic collection, analysis, and interpretation of data,
often incidence of cases of disease or infection. Surveil-
lance data are used to plan, implement, and evaluate the
progress in public health programs.
Per the WHO Global Malaria Eradication Program: In
malaria eradication terminology, surveillance was that part
of the program aimed at the discovery, investigation, and
elimination of continuing transmission, the prevention and
cure of infections, and the final substantiation of claimed
eradication. The individual functions of surveillance are
case detection, parasitological examination, antimalarial
drug treatment, epidemiological investigation, entomo-
logical investigation, elimination of foci by either residual
spraying or mass drug administration, case follow-up, and
community follow-up. In this definition, surveillance is
seen as an intervention [16].
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timely reporting exist, it is crucial that surveillance systems respond
effectively to detected foci of infections and ultimately to individual
infections in order to reduce transmission to a reproduction rate
(R0)o f,1. Although many programmatic responses to detected
infections exist, there is neither a systematic description of such
responses nor a well-defined evidence base to suggest the optimal
strategic approach. For surveillance to be effective as an
intervention, research on useful and efficient modes of both
detection and response must be undertaken [20]. At the most basic
level, it is currently unclear when programs transitioning to very
low transmission conditions should add active case and infection
detection to their response strategies, and whether additional
vector control interventions are needed [21]. The evolution of
these actions and the optimal sequence and mix needs further
evaluation as is also discussed in the malERA paper on modeling
[22].
Finally, countries embarking on malaria elimination must
establish a system for continuous data validation to identify
problems and to prepare for the process of certification of
elimination [23,24]. The concept of ‘‘good surveillance practices’’
should be implemented early to facilitate evaluation of the quality
of the surveillance programs in the process of certification. Any
system needs to be responsive and iterative to improve
surveillance.
Tools to Improve the Efficacy and Efficiency of
Malaria Elimination
The overall strategic approach and mix of actions to address
transmission is critical, but the identification and development of
key tools and actions to optimize these strategic actions is equally
important. Improved diagnostics for screening and surveillance,
optimal use of drugs to reduce transmission [25], better mapping
and use of mapping to track foci of infections, and improved
communications for timely sharing of information and response
are all important.
Diagnostics
Tests that are sensitive enough to detect asymptomatic
infections (as opposed to symptomatic infections or cases) are
needed for elimination [26]. Ultimately, for simplicity and
efficiency, it will be preferable to have the same test for both
surveillance and case management. Elimination has already been
achieved in some areas of low endemicity using currently available
diagnostic tools (principally microscopy), but future efforts will
include areas of previously high transmission that have achieved
significant reductions through intervention scale-up. Existing
diagnostic tools will need to be improved to achieve elimination
in these more challenging transmission areas. Microscopy has
some limitations in human resource capacity needs, sensitivity and
ease of widespread use at the community level. Similarly, currently
available rapid diagnostic tests (RDTs) have limited sensitivity
compared with PCR, and need to be improved in terms of
specificity, ease of use, cost, shelf stability under tropical
conditions, Plasmodium vivax detection, ability to return to negative
after treatment, and multispecies detection capacity where this is
an issue [27]. As discussed in the malERA paper on Diagnoses and
Diagnostics [11], rapid techniques not requiring blood sampling
could provide major breakthroughs.
There is also a need to address issues around effective
supervision and support. In particular, as transmission decreases,
residual foci of infection may cluster in difficult-to-access
populations that are underserved and less likely to access the
health system. Strategies need to be developed and tested for
improving access to and tracking of these populations for screening
and surveillance of infection.
Finally, for eradication, diagnostic tools to measure transmission
and its interruption will be critical. There is considerable interest
Table 1. Program activities and methods for transmission reduction in populations.
Potential Activity Description and Purpose
Prevalence surveys Usually population-based surveys to stratify risk, evaluate impact of interventions, and track
progress towards elimination
Active case detection Regular efforts to ascertain fever and infection in the community
Focused screening for infections (‘‘active infection detection’’) Targeted search for main sources of rare cases (of Pf, Pv, drug-resistant Pf) and eliminating them
Case investigation Detecting infections/cases around index cases for response
Mass screening and treatment Screening large segments of the population to find and treat cases
Mass drug administration
a Administration of treatment to large segments of the populations regardless of infection status to
reduce infections in a population with a relatively high infection rate
Surveillance for drug-resistant parasites Enrollment of cases and follow-up of presence, density, or absence of parasites for in vivo
resistance surveillance to assess treatment efficacy
Detection of gametocytaemia
b Find infections that contribute to ongoing transmission so that they can be treated to reduce
transmission
Confirmation of elimination/detection of reintroduction
c Measurement of ongoing infection and transmission through sampling and use of biomarkers
such as DNA or serology
Border screening/transit screening
d Rapid diagnostic testing of people crossing borders to allow immediate treatment of positives
aNote that mass drug administration is controversial for a variety of reasons but is presented here for completeness sake as it has been used to some benefit in the past
(see also [25]).
bSee also [11] and [25].
cSee also [11] and [44].
dSee also [12].
Pf, P. falciparum; Pv, P. vivax.
doi:10.1371/journal.pmed.1000400.t001
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diagnosis of recent infection (incidence). Serology and other
potential biomarkers are discussed in more detail below.
Mapping and Stratification
Maps of the global distribution of P. vivax and Plasmodium
falciparum that were generated by the Malaria Atlas Project have
recently been published, but there is little research on how best to
use these maps in the context of elimination [28,29], and current
mapping initiatives are limited by data availability, especially for
scenarios that require high resolution. Maps can help define which
low transmission areas are possible elimination targets, and can
define the limits of adverse conditions for transmission, such as
aridity and temperature. Maps can also help to determine where
additional survey work is necessary for better spatial resolution of
endemicity.
On a global scale, mapping malaria distribution will allow
stratification to inform decision making and allow for interventions
to be targeted or prioritized [29,30]. When allied with modeling,
such maps can indicate which combinations of interventions may
be most appropriate and how much these will cost [22,31].
However, for optimal utility, maps will need to be sensitive to
different ecological scenarios and should provide enough detail of
the principal factors governing transmission. From a technical
point of view, more detailed maps are feasible, and linking
mapping databases with other technologies such as Google will
increase ease of access to mapping information.
For maps at regional or national levels, the spatial resolution of
the information required is greater than that required for global
scale risk mapping. Integration of mapping activities with the
outputs of surveillance systems and other data sources (for
example, intervention coverage and vector distribution) can
provide the level of detail required to support effective elimination
efforts. However, the incorporation of existing techniques for rapid
mapping and the development of methods for optimal information
dissemination to all levels of the malaria control programme
remain major research challenges, as does the need to update
protocols that do not currently incorporate our ability to image,
map, and display information remotely, technologies that have
been revolutionized since the Global Malaria Eradication
Program.
As we progress closer to the goal of elimination, finer scale
mapping will be required to identify residual foci [32]. Geograph-
ical reconnaissance remains part of control and elimination
attempts in many countries and relies on local knowledge to
make largely hand-drawn maps of potential foci and known vector
breeding sites. This approach needs to be modernized to include a
simple, user-friendly, and consistent methodology for micro-
mapping. High resolution satellite imagery can detect households
and water bodies at unprecedented spatial resolutions and thus
replace some of the logistic burden in reconnaissance required to
support elimination activities [33]. The use of maps to help find
rare events such as individual cases of malaria is also a very poorly
developed area that needs further research. Efficient signatures of
transmission hotspots or disease foci (environmental, entomolog-
ical, and human) are also not well known, so a final challenge will
be to integrate novel monitoring and evaluation metrics with the
existing mapping suite.
Communication Technologies
Technological advances in communications and reporting
systems (data collection, aggregation, and dissemination) offer
potential improvements for surveillance in the context of
elimination and eradication. Other prerequisites for good
communication and reporting include basic health systems, and
the capacity to analyze and use data to improve program
performance. Most importantly, it is only the relevant and useful
surveillance information that is required for prompt and timely
communication.
Examples of potential enhancements to improve timely
reporting include widespread implementation of cell phone
technology [34], which has been used with considerable success
in some areas such as Zanzibar and Madagascar to provide cluster
detection and response [35]. Systems such as real-time internet
Web-based reporting are also being explored. As noted above, the
development of methods to integrate surveillance reporting
technology with mapping tools is a priority. Critically, systems
developed for collection, reporting, analysis, and dissemination of
information must be structured so that they enhance decision-
making and programmatic direction at the local (district) level. In
addition, these systems must enhance the capacity of the program
to provide useful and timely information to policy makers so that
program status and progress towards elimination is clear and well
explained [36].
Resistance and High-Risk Populations
Tracking antimalarial drug resistance is an important activity in
the context of malaria control, but it becomes less important in
situations where there are relatively few cases who must all receive
curative treatment. Thus, as elimination is approached, all
outpatient therapy might be better administered as ‘‘directly
observed therapy’’ as with tuberculosis. Because of inconsistent
and inadequate access to health systems, difficult-to-access
populations may be at increased risk of harbouring individuals
with drug-resistant parasites. Strategies to improve access to these
populations were discussed earlier (see also [25]).
As elimination is approached, declining transmission and thus
fewer cases pose considerable challenges to monitoring for drug
resistance because recruitment of sufficient numbers of patients is
difficult and thus studies are prolonged and expensive. Simple
drug efficacy protocols worked into routine surveillance activities
at sentinel sites may be of some use; follow-up of all treated cases
may be another approach to ensure that individuals have cleared
parasites [37]. Molecular markers for resistance could be useful for
population-level screening, although new assays relevant to
current treatment drugs, particularly the artemisinins, need to be
developed. Simple field PCR-based tools would be of use, both for
resistance testing and to differentiate recrudescence from new
infections [11].
Although no vaccine is currently available, it is likely that
vaccines may be in use in the next decade. A challenge will be to
monitor vaccines for efficacy against antigenically diverse parasites
in the population, for their preventive effects against severe
disease, and for their effects in settings with changing transmission,
as well as for their effects on transmission itself (see also [38]).
Newer molecular biology approaches may be useful in which
human genes are used to predict immunological responses. Case
control methodology can also be used to evaluate vaccine
performance [39].
Tools for Transmission Measurement: Metrics
Accurate measurement of malaria transmission is essential for
monitoring and evaluation of malaria control programs that are
approaching interruption of transmission and elimination. Past
and present metrics for measuring malaria transmission in humans
in endemic regions were recently systematically reviewed [14] and
include: the proportion of individuals in a population with a
palpable spleen (spleen rate); the proportion of individuals in a
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time (parasite rate [PR]); and the annual parasite incidence ([API],
the product of the annual blood examination rate and slide
positivity rate) [13,14]. The entomological inoculation rate ([EIR],
the number of infective bites per person per unit time) remains the
gold standard measure of transmission.
A valid metric, or a combination of metrics, for measuring the
interruption of transmission nationally or subnationally is critical
as elimination is approached; but the existing metrics all have
serious limitations when transmission is approaching zero,
including the EIR, which is difficult, expensive, and virtually
impossible to measure when there is very low transmission.
For example, API (or alternatively annual case incidence) is an
important metric of transmission that can be obtained from routine
surveillance reporting even when the PR falls below 5%. However,
to ascertain API accurately, all cases in the population must be
identified through comprehensive and complete surveillance of the
target population, ideally using both passive and active detection.
API ascertained through passive detection alone only records those
symptomatic individuals who are captured through the routine
surveillance system and would, therefore, provide a biased (too low)
estimate of transmission for the entire target population. Addition-
ally, its failure to detect individuals with asymptomatic infections in
the population would critically hinder the clearance of parasites
from human reservoirs when working towards elimination.
Similarly, to obtain an unbiased estimate of PR for a target
population where the combination of passive and active detection
is incomplete, probability sampling of the population is required
(see next section also), but this is problematic when transmission is
reduced to nonrandom residual foci of cases. Furthermore, using
PR ascertained from probability biomarker surveys for validation
of freedom from disease is challenging, with sample size and
resultant uncertainty dependent on the probability of committing
a type 1 and 2 error, the size of the population being sampled, and
the sensitivity and specificity of the diagnostic test [40]. Thus,
unless extremely large sample sizes are used, PR will provide
imprecise measures at near zero transmission. Research is needed,
therefore, to develop new metrics for transmission and to improve
or modify data systems for these kinds of measurements.
Tools for Transmission Measurement: Sampling and
Surveys
To assess progress in intervention scale-up, nationally repre-
sentative household surveys, such as the Malaria Indicator Survey
(MIS), Demographic and Health Survey (DHS), and the UNICEF
Multiple Indicator Cluster Survey (MICS), are recommended data
collection instruments, Such surveys can provide population-
based, relatively accurate, estimates of malaria intervention
coverage, and parasite infection prevalence in the population,
and should be useful in assessing sustained coverage of malaria
interventions on a periodic basis, typically every 3–5 years.
However, once scale-up has been achieved and infection
prevalence is approaching zero, or has been disrupted, such
national surveys, with sample sizes typically of at least 2,000
households, would not be feasible for routine monitoring of low
and/or focal malaria transmission. Alternative sampling methods
for ascertaining population-based measures of malaria transmis-
sion are therefore needed. Ideally, such novel sampling strategies
would approximate a ‘‘probability survey’’ (a survey having a
known, nonzero probability of selection of all individuals for which
it is desired to obtain estimates), while remaining logistically
feasible to implement on a routine basis.
Once transmission has been interrupted, population-based
collection of biological samples for detection of present infections,
or serology for detection of past exposure and infection, could
prove important for routine monitoring of populations, although
improved assays will be required. Such approaches might include
routine sampling of populations through antenatal clinics,
immunization programs, and schools. Assessment of the validity
of these new approaches for obtaining relatively unbiased
population estimates will be needed.
To maintain interrupted transmission or elimination, malaria
control programs need to be able to obtain representative and
precise estimates of parasite exposure and present infections among
mobile populations, especially those that frequently cross national
borders. Although respondent-driven sampling (a sampling ap-
proach in which existing study subjects recruit future subjects from
among their acquaintances) has been used for ascertaining point
estimates among hidden populations, this approach would likely be
inappropriate for monitoring malaria transmission among mobile
populations. One approach that should be tested for routine
Box 2. Summary of the Research and
Development Agenda for Monitoring,
Evaluation, and Surveillance
N Update the malaria monitoring and evaluation Frame-
work to include transmission reduction, and develop key
data elements for a surveillance system from a system-
atic review of previous elimination attempts
N Systematically review lessons learned from experiences
with surveillance as an intervention to determine how it
can be tailored to various programmatic settings
N Identify appropriate program time points for introduc-
tion of malaria infection detection in active or passive
modes
N Develop improved diagnostic tools for use in monitoring
and evaluation and surveillance, focusing on practical
field-ready tools for detection of asymptomatic infection
N Develop information systems to monitor malaria infec-
tions, facilitate timely local program decisions and
responses to reduce transmission
N Develop methods, indicators, and shareable databases
for parasite strain information to better track transmis-
sion
N Develop methods for accessing and tracking population
movements and quantifying their contribution and risk
of malaria transmission
N Explore how maps can be constructed to: show the
probability of a threshold of transmission being exceed-
ed; incorporate a wider range of metrics such as
serological and entomological data; assess cost-effec-
tiveness of national stratification initiatives based on
remotely sensed satellite data
N Perform a systematic review to assess and compare
metrics of malaria transmission at near zero transmission
levels; research the validity of novel metrics to measure
transmission at near zero levels, and to measure
transmission potential within areas where transmission
has been eliminated
N Assess the precision, bias, feasibility, and cost-effective-
ness of novel sampling methods for routine monitoring
of present and past infections in target populations,
including mobile populations
N Conduct research to develop biomarkers such as DNA-
based methods or serology as monitoring and evalua-
tion and surveillance tools
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variation of traditional two-stage cluster sampling in which the
primary sampling units are time-location settings where mobile
and/or hidden populations are known to congregate. Assessment of
the accuracy of TLS estimates of parasite infection prevalence
among mobile populations is needed, as well as cost-effectiveness in
relation to other sampling methods.
Biomarkers for Transmission Measurement
Serologic methods are currently an area of renewed interest as a
potentially valuable tool for robust transmission measurement.
Serology has been used to measure malaria exposure in humans for
many years and was prominent in early elimination attempts
[41,42]. But, as these elimination attempts were scaled back, so was
the use of serological characterization. With little use over several
decades, these serologic assays lacked standardized, reproducible,
and objective methods [43]. Recent technological improvements
(for example, techniques that facilitate the production of antigens)
mean that serology has now become a much more robust tool for
transmission measurement [44]. However, there is a need to
standardize protocols and antigens; currently there are many
different methodologies with associated variation in results.
Fundamental issues relating to the generation and maintenance of
antibody responses in children and adults also need to be addressed.
Other research and development needs include the development
of serological assays that are sensitive and specific for different
Plasmodium species. Assays also need to be developed that show
cumulative exposure to the parasite, as well as recent changes in
transmission intensity by measuring both the prevalence and the
magnitudeoftheantibodyresponse.Serologicalmethodsmightalso
be developed that distinguish between relapse and new infection
with P. vivax by measuring exposure to mosquito saliva through the
detection of antisaliva antibodies.
PCR or similar molecular amplification–based methods may
also prove useful for the measurement of transmission reduction/
interruption, especially if pooled sampling and high-throughput
automated techniques are used to handle large numbers of
samples [45]. There is limited experience to date with these
methods as tools to measure transmission; further research may
help to elucidate their potential.
For all biomarkers, the most desirable assays would not require
blood sampling so research into biomarkers in saliva or other
bodily fluids is needed. Finally, for all biomarkers, there is a need
to develop criteria that define an area as ‘‘malaria free.’’
Concluding Remarks
The new strategies proposed in this paper by the malERA
Consultative Group on Monitoring, Evaluation, and Surveillance
for eradication have major implications for implementation, and
research is needed to test best systems of delivery for acceptability,
feasibility, efficiency, and cost-effectiveness. Box 2 draws our
discussions together in the form of a research and development
agenda for monitoring, evaluation, and surveillance.
Acknowledgments
The Malaria Eradication Research Agenda (malERA) Consultative Group
on Monitoring, Evaluation, and Surveillance was chaired by Laurence
Slutsker, US Centers for Disease Control and Prevention, Atlanta,
Georgia, USA. The paper was written on the basis of consultations during
malERA meetings held in Barcelona, Spain (January, 2009) and Basel,
Switzerland (October, 2009).
Members of the writing group were:
Pedro L. Alonso, Barcelona Centre for International Health Research,
(Hospital Clı ´nic, Universitat de Barcelona), Barcelona, Spain and Centro
de Investigac ¸ao em Saude da Manhic ¸a, Mozambique; Hoda Youseff Atta,
World Health Organization/EMRO, Cairo, Egypt; Chris Drakeley,
London School of Hygiene & Tropical Medicine, London, UK; Thomas
Eisele, Tulane University, New Orleans, Louisiana, USA; Simon I. Hay,
Spatial Ecology and Epidemiology Group, Department of Zoology,
University of Oxford, Oxford, UK; Mario Henry Rodrı ´guez Lu ´pez,
Instituto Nacional de Salud Pu ´blica, Cuernavaca, Mexico; Sylvia Meek,
Malaria Consortium, London, UK; Richard Steketee, PATH MACEPA,
Ferney Voltaire, France; Laurence Slutsker (chair), US Centers for Disease
Control and Prevention, Atlanta, Georgia, USA.
Participants in the malERA meetings and extra contributors:
Barcelona, Spain (January 2009), Monitoring, Evaluation, and
Surveillance meeting: Pedro L. Alonso, Barcelona Centre for
International Health Research (Hospital Clı ´nic, Universitat de Barcelona),
Barcelona, Spain and Centro de Investigac ¸ao em Saude da Manhic ¸a,
Mozambique; Hoda Youseff Atta, World Health Organization/EMRO,
Cairo, Egypt; Quique Bassat, Barcelona Centre for International Health
Research (Hospital Clı ´nic, Universitat de Barcelona), Barcelona, Spain;
Nathan Bakyaita, World Health Organization/AFRO, Brazzaville, Congo;
John Paul Clark, World Bank, Washington (D.C.), USA; Ogobara K.
Doumbo, University of Bamako, Bamako, Mali; Chris Drakeley, London
School of Hygiene & Tropical Medicine, London, UK; Erin Lynn Eckert,
Macro International, Calverton, Maryland, USA; Thomas Eisele, Tulane
University, New Orleans, Louisiana, USA; Khota Gausi, World Health
Organization/AFRO, Harare, Zimbabwe; Caterina Guinovart, Barcelona
Centre for International Health Research (Hospital Clı ´nic, Universitat de
Barcelona), Barcelona, Spain; Ned Hayes, Barcelona Centre for Interna-
tional Health Research (Hospital Clı ´nic, Universitat de Barcelona),
Barcelona, Spain; Albert Kilian, Malaria Consortium, London, UK;
Marcel Lama, GFTAM, Vernier, Switzerland; Sylvia Meek, Malaria
Consortium, London, UK; John Miller, PATH MACEPA, Lusaka,
Zambia; Bernard Nahlen, USAID-PMI, Washington (D.C.), USA; Mac
Otten, World Health Organization, Geneva, Switzerland; Amy Ratcliffe,
Bill & Melinda Gates Foundation, Seattle, Washington, USA; Mario
Henry Rodrı ´guez Lo ´pez, Instituto Nacional de Salud Pu ´blica, Cuernavaca,
Me ´xico; Laurence Slutsker (chair), US Centers for Disease Control and
Prevention, Atlanta, Georgia, USA; Madeleine Thomson, International
Research Institute for Climate and Society (IRI)-Columbia University,
New York, New York, USA.
Basel, Switzerland (October 2009) Monitoring, Evaluation
and Surveillance, writing meeting: Pedro L. Alonso, Barcelona
Centre for International Health Research (Hospital Clı ´nic, Universitat de
Barcelona), Barcelona, Spain and Centro de Investigac ¸ao em Saude da
Manhic ¸a, Mozambique; Hoda Youseff Atta, World Health Organization/
EMRO, Cairo, Egypt; Chris Drakeley, London School of Hygiene &
Tropical Medicine, London, UK; Thomas Eisele, Tulane University, New
Orleans, Louisiana, USA; Sylvia Meek, Malaria Consortium, London,
UK; Laurence Slutsker (chair), US Centers for Disease Control and
Prevention, Atlanta, Georgia, USA.
Extra contributors: Brian Greenwood, London School of Hygiene &
Tropical Medicine, London, UK; Marcel Tanner, Swiss Tropical and
Public Health Institute and University of Basel, Basel, Switzerland.
Author Contributions
LS is the corresponding author on behalf of the malERA Consultative
Group on Monitoring, Evaluation, and Surveillance. Chaired the group:
LS. ICMJE criteria for authorship read and met: PLA, CD, TE, HYA,
SM, LS, RS, MHR, SH. Participated in one or more discussion meetings
resulting in the writing of this article: The malERA Consultative Group on
Monitoring, Evaluation, and Surveillance.
References
1. Roll Back Malaria Partnership (2010) Framework for monitoring progress and
evaluating outcomes and impact. Available: http://www.rollbackmalaria.org/
cmc_upload/0/000/012/168/m_e_en.pdf.
2. Feachem RGA, Phillips AA, Targett GA, eds (2010) Shrinking the malaria map:
a prospectus on malaria elimination. Available: http://www.malariaelimina
tiongroup.org.
PLoS Medicine | www.plosmedicine.org 7 January 2011 | Volume 8 | Issue 1 | e10004003. Roll Back Malaria Partnership (2010) The global malaria action plan. Available:
http://www.rollbackmalaria.org/gmap/.
4. WHO (2008) Global malaria control and elimination: report of a technical
review. Geneva: World Health Organization Press.
5. Hopkins DR, Ruiz-Tiben E, Downs P, Withers PC, Jr., Roy S (2008)
Dracunculiasiseradication:neglectednolonger.AmJTropMedHyg79:474–479.
6. Henderson DA (1999) Lessons from the eradication campaigns. Vaccine 17:
S53–S55.
7. Cochi SL, Kew O (2008) Polio today: are we on the verge of global eradication?
JAMA 300: 839–841.
8. Breman JG, Quadros CA, Dowdle WR, Foege WH, Henderson DA, et al.
(2011) The role of research in viral disease eradication and elimination
programs: Lessons for malaria eradication. PLoS Med 8: e1000405.
doi:10.1371/journal.pmed.1000405.
9. Na ´jera J, Gonza ´lez-Silva M, Alonso PL (2011) Some lessons for the future from
the Global Malaria Eradication Programme (1955–1969). PLoS Med 8:
e1000412. doi:10.1371/journal.pmed.1000412.
10. Atta H, Zamani G (2008) The progress of Roll Back Malaria in the Eastern
Mediterranean Region over the past decade. East Mediterr Health J 14:
S82–S89.
11. The malERA Consultative Group on Diagnoses and Diagnostics (2011) A
research agenda for malaria eradication: Diagnoses and diagnostics. PLoS Med
8: e1000396. doi:10.1371/journal.pmed.1000396.
12. The malERA Consultative Group on Cross-cutting Issues for Eradication (2011)
A research agenda for malaria eradication: Cross-cutting issues for eradication.
PLoS Med 8: e1000404. doi:10.1371/journal.pmed.1000404.
13. Pampana E (1969) A Texbook of malaria eradication. London: Oxford
University Press.
14. Hay SI, Smith DL, Snow RW (2008) Measuring malaria endemicity from
intense to interrupted transmission. Lancet Infect Dis 8: 369–378.
15. WHO (1963) Terminology of malaria and malaria eradication: Report of a
drafting committee. Geneva: WHO.
16. Yekutiel P (1960) Problems of epidemiology in malaria eradication. Bull WHO
22: 669–683.
17. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, et al. (2010) A large
proportion of asymptomatic Plasmodium infections with low and sub-microscopic
parasite densities in the low transmission setting of Temotu Province, Solomon
Islands: Challenges for malaria diagnostics in an elimination setting. Malar J 9:
254.
18. Centers for Disease Control and Prevention, Filler SJ, MacArthur JR, Parise M,
Wirtz R, et al. (2006) Locally acquired mosquito-transmitted malaria: A guide
for investigations in the United States. MMWR Recomm Rep 55: 1–9.
19. Ceccato P, Connor SJ, Jeanne I, Thomson MC (2005) Application of
geographical information systems and remote sensing technologies for assessing
and monitoring malaria risk. Parassitologia 47: 81–96.
20. Macauley C (2005) Aggressive active case detection: A malaria control strategy
based on the Brazilian model. Soc Sci Med 60: 563–573.
21. Betanzos-Reyes AF, Rodrı ´guez MH, Duran-Arenas LG, Herna ´ndez-Avila JE,
Me ´ndez-Galva ´n JF, et al. (2007) Comparative analysis of two alternative models
for epidemiological surveillance in the Mexican Malaria Control program.
Health Policy 80: 465–482.
22. The malERA Consultative Group on Modeling (2011) A research agenda for
malaria eradication: Modeling. PLoS Med 8: e1000403. doi:10.1371/
journal.pmed.1000403.
23. WHO (2007) United Arab Emirates certified malaria-free. Wkly Epidemiol Rec
4: 25–32.
24. WHO (2007) Guidelines on the elimination of residual foci of malaria
transmission. Cairo: World Health Organization Regional Office for the
Eastern Mediterranean (EMRO). Technical Publications Series 33, Available:
http://www.emro.who.int/dsaf/dsa742.pdf.
25. The malERA Consultative Group on Drugs (2011) A research agenda for malaria
eradication: Drugs. PLoS Med 8: e1000402. doi:10.1371/journal.pmed.1000402.
26. Perkins MD, Bell DR (2008) Working without a blindfold: The critical role of
diagnostics in malaria control. Malaria J 11: S5.
27. Bell D, Wongsrichanalai C, Barnwell JW (2006) Ensuring quality and access for
malaria diagnosis: how can it be achieved? Nat Rev Microbiol 4: 682–695.
28. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, et al. (2009) A world
malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6: e1000048.
doi:10.1371/journal.pmed.1000048.
29. Hay SI, Snow RW (2006) The Malaria Atlas Project: Developing global maps of
malaria risk. PLoS Med 3: e473. doi:10.1371/journal.pmed.0030473.
30. Noor AM, Mutheu JJ, Tatem AJ, Hay SI, Snow RW (2009) Insecticide-treated
net coverage in Africa: Mapping progress in 2000–07. Lancet 373: 58–67.
31. Smith DL, Hay SI, Noor AM, Snow RW (2009) Predicting changing malaria
risk after expanded insecticide-treated net coverage in Africa. Trends Parasitol
25: 511–516.
32. Gaudart J, Poudiougou B, Dicko A, Ranque S, Toure O, et al. (2006) Space-
time clustering of childhood malaria at the household level: A dynamic cohort in
a Mali village. BMC Public Health 6: 286.
33. Rogers DJ, Randolph SE, Snow RW, Hay SI (2002) Satellite imagery in the
study and forecast of malaria. Nature 7: 710–715.
34. Blaya JA, Fraser HS, Holt B (2010) E-health technologies show promise in
developing countries. Health Affairs 29: 244–251.
35. Randrianasolo L, Raoelina Y, Ratsitorahina M, Ravolomanana L,
Andriamandimby S, et al. (2010) Sentinel surveillance system for early outbreak
detection in Madagascar. BMC Public Health 10: 31.
36. The malERA Consultative Group on Health Systems and Operational Research
(2011) A research agenda for malaria eradication: Health systems and operational
research. PLoS Med 8: e1000397. doi:10.1371/journal.pmed.1000397.
37. WHO (2009) Methods for surveillance of antimalarial drug efficacy. Geneva:
World Health Organization.
38. ThemalERAConsultativeGroup on Vaccines(2011)A researchagenda formalaria
eradication: Vaccines. PLoS Med 8: e1000398. doi:10.1371/journal.pmed.1000398.
39. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, et al. (1993)
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current
recommendations. JAMA 270: 1826–1831.
40. Cameron AR, Baldock FC (1998) A new probability formula for surveys to
substantiate freedom from disease. Prev Vet Med 34: 1–17.
41. Bruce-Chwatt LJ, Dodge JS, Draper CC, Topley E, Voller A (1972) Sero-
epidemiological studies on population groups previously exposed to malaria.
Lancet 1: 512–515.
42. Bruce-Chwatt LJ, Draper CC, Avramidis D, Kazandzoglou O, et al. (1975)
Sero-epidemiological surveillance of disappearing malaria in Greece. J Trop
Med Hyg 78: 194–200.
43. Drakeley C, Cook C (2009) Potential contribution of sero-epidemiological
analysis for monitoring malaria control and elimination: historical and current
perspectives. Adv Parasitol 69: 299–352.
44. Corran P, Coleman P, Riley E, Drakeley C (2007) Serology: A robust indicator
of malaria transmission intensity? Trends Parasitol 23: 575–582.
45. Taylor SM, Juliano JJ, Trottman PA, Griffin JB, Landis SH, et al. (2010) High-
throughput pooling and real-time PCR-based strategy for malaria detection.
J Clin Microbiol 48: 512–519.
PLoS Medicine | www.plosmedicine.org 8 January 2011 | Volume 8 | Issue 1 | e1000400